Iovance Biotherapeutics (IOVA) Interest & Investment Income (2014 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Interest & Investment Income of $1.3 million for Q1 2026, down 58.6% year-over-year from $3.2 million in Q1 2025, and down 23.39% quarter-over-quarter from $1.7 million in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) Interest & Investment Income (2014 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Interest & Investment Income for 13 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 58.6% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $8.4 million (down 58.22% YoY), while the FY2025 annual figure was $10.3 million, down 49.16% from the prior year.
- Interest & Investment Income retreated to $1.3 million in Q1 2026 per IOVA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $9.6 million in Q4 2024 and bottomed at $106000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.8 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2023 — Interest & Investment Income jumped 3188.68% — and 2025, when it sank 81.83%.
- Iovance Biotherapeutics' Interest & Investment Income stood at $1.7 million in 2022, then jumped by 81.6% to $3.1 million in 2023, then soared by 207.09% to $9.6 million in 2024, then tumbled by 81.83% to $1.7 million in 2025, then slipped by 23.39% to $1.3 million in 2026.
- Business Quant data shows IOVA's Interest & Investment Income at $1.3 million in Q1 2026, $1.7 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | 3.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 9.58 Mn |
| Sep 30, 2024 | 4.01 Mn |
| Jun 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.34 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 3.08 Mn |
| Mar 31, 2023 | 3.49 Mn |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 777,000.00 |
| Jun 30, 2022 | 385,000.00 |
| Mar 31, 2022 | -1.74 Mn |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 120,000.00 |